Use of Active Surveillance vs Definitive Treatment Among Men With Low- and Favorable Intermediate-Risk Prostate Cancer in the US Between 2010 and 2018.
作者信息
Al Hussein Al Awamlh Bashir, Barocas Daniel A, Zhu Alec, Tosoian Jeffrey J, Ponsky Lee, Negoita Serban, Shoag Jonathan E
机构信息
Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee.
Department of Urology, New York-Presbyterian Hospital, Weill Cornell Medicine, New York, New York.
出版信息
JAMA Intern Med. 2023 Jun 1;183(6):608-611. doi: 10.1001/jamainternmed.2022.7100.
Abstract
摘要
相似文献
1
Use of Active Surveillance vs Definitive Treatment Among Men With Low- and Favorable Intermediate-Risk Prostate Cancer in the US Between 2010 and 2018.2010年至2018年美国低风险和有利中风险前列腺癌男性患者中主动监测与确定性治疗的使用情况
JAMA Intern Med. 2023 Jun 1;183(6):608-611. doi: 10.1001/jamainternmed.2022.7100.
2
More Judicious Use of Expectant Management for Localized Prostate Cancer during the Last 2 Decades.在过去 20 年中，更明智地使用期待治疗管理局限性前列腺癌。
J Urol. 2017 Mar;197(3 Pt 1):614-620. doi: 10.1016/j.juro.2016.10.067. Epub 2016 Oct 27.
3
Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer.基于人群的研究：低危和中危前列腺癌采用主动监测和观察等待的使用情况及其决定因素。
J Urol. 2013 Nov;190(5):1742-9. doi: 10.1016/j.juro.2013.05.054. Epub 2013 May 30.
4
National Comprehensive Cancer Network® Favorable Intermediate Risk Prostate Cancer-Is Active Surveillance Appropriate?国家综合癌症网络®有利的中危前列腺癌——是否适合主动监测？
J Urol. 2018 May;199(5):1196-1201. doi: 10.1016/j.juro.2017.12.049. Epub 2017 Dec 26.
5
Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer.主动监测在中危前列腺癌患者中的应用及早期死亡率结果。
Cancer. 2019 Sep 15;125(18):3164-3171. doi: 10.1002/cncr.32202. Epub 2019 May 31.
6
Active surveillance in favorable intermediate risk prostate cancer: outstanding questions and controversies.在有利的中等风险前列腺癌中进行主动监测：悬而未决的问题和争议。
Curr Opin Oncol. 2022 May 1;34(3):219-227. doi: 10.1097/CCO.0000000000000827. Epub 2022 Mar 9.
7
An evidence review of active surveillance in men with localized prostate cancer.局限性前列腺癌男性患者主动监测的证据综述。
Evid Rep Technol Assess (Full Rep). 2011 Dec(204):1-341.
8
Re: Risk Group and Death from Prostate Cancer: Implications for Active Surveillance in Men with Favorable Intermediate-Risk Prostate Cancer.关于：风险分组与前列腺癌死亡：对低危中危前列腺癌男性主动监测的启示
J Urol. 2016 Aug;196(2):412-3. doi: 10.1016/j.juro.2016.05.068. Epub 2016 May 18.
9
Population-Based Assessment of Determining Treatments for Prostate Cancer.基于人群的前列腺癌治疗方法评估。
JAMA Oncol. 2015 Apr;1(1):60-7. doi: 10.1001/jamaoncol.2014.192.
10
Assessing the relationship between statin use and oncologic outcomes among men electing active surveillance for localized prostate cancer.评估在选择主动监测的局限性前列腺癌男性中，他汀类药物的使用与肿瘤学结果之间的关系。
Prostate Cancer Prostatic Dis. 2019 Dec;22(4):617-623. doi: 10.1038/s41391-019-0147-0. Epub 2019 Apr 17.
引用本文的文献
1
A Personalized, Risk-Based Approach to Active Surveillance for Prostate Cancer with Takeaways from Broader Oncology Practices: A Mixed Methods Review.一种基于风险的前列腺癌主动监测个性化方法及更广泛肿瘤学实践的经验教训：混合方法综述
J Pers Med. 2025 Feb 25;15(3):84. doi: 10.3390/jpm15030084.
2
Personalized Dynamic Prediction Model for Biopsy Timing in Patients With Prostate Cancer During Active Surveillance.前列腺癌患者主动监测期间活检时机的个性化动态预测模型
JAMA Netw Open. 2025 Jan 2;8(1):e2454366. doi: 10.1001/jamanetworkopen.2024.54366.
3
Cancer statistics, 2025.2025年癌症统计数据。
CA Cancer J Clin. 2025 Jan-Feb;75(1):10-45. doi: 10.3322/caac.21871. Epub 2025 Jan 16.
4
Ascertaining provider-level implicit bias in electronic health records with rules-based natural language processing: A pilot study in the case of prostate cancer.利用基于规则的自然语言处理确定电子健康记录中医疗服务提供者层面的隐性偏见：前列腺癌案例的一项试点研究。
PLoS One. 2024 Dec 30;19(12):e0314989. doi: 10.1371/journal.pone.0314989. eCollection 2024.
5
Active Surveillance or Watchful Waiting for Intermediate-Risk Prostate Cancer, 2010-2020.2010 - 2020年对中危前列腺癌进行主动监测或观察等待
JAMA. 2024 Dec 17;332(23):2033-2036. doi: 10.1001/jama.2024.20580.
6
Lifetime Health and Economic Outcomes of Biparametric Magnetic Resonance Imaging as First-Line Screening for Prostate Cancer : A Decision Model Analysis.基于双参数磁共振成像的前列腺癌一线筛查的终生健康和经济结局：决策模型分析。
Ann Intern Med. 2024 Jul;177(7):871-881. doi: 10.7326/M23-1504. Epub 2024 Jun 4.
7
Using active surveillance for Gleason 7 (3+4) prostate cancer: A narrative review.对 Gleason 7（3+4）前列腺癌采用主动监测：一项叙述性综述。
Can Urol Assoc J. 2024 Apr;18(4):135-144. doi: 10.5489/cuaj.8539.
8
Functional Outcomes After Localized Prostate Cancer Treatment.局限性前列腺癌治疗后的功能结局。
JAMA. 2024 Jan 23;331(4):302-317. doi: 10.1001/jama.2023.26491.
9
Opportunistic prostate-specific antigen testing in Norwegian men: a public health challenge.挪威男性机会性前列腺特异性抗原检测：公共卫生挑战。
BJU Int. 2024 Jan;133(1):104-111. doi: 10.1111/bju.16211. Epub 2023 Nov 2.
10
Patient and Context Factors in the Adoption of Active Surveillance for Low-Risk Prostate Cancer.患者和环境因素对低危前列腺癌主动监测策略的影响。
JAMA Netw Open. 2023 Oct 2;6(10):e2338039. doi: 10.1001/jamanetworkopen.2023.38039.
Zotero 插件